Table 4.
Univariate analysis of overall survival.
| Variable (Reference) | Hazard Ratio | 95% CI | p Value |
|---|---|---|---|
| Age (Mean) | 1.09 | 1.04–1.14 | <0.001 |
| Gender (Male/Female) | 0.96 | 0.46–2.00 | 0.913 |
| Localization (Right/Left) | 0.78 | 0.39–1.55 | 0.479 |
| Stage (II/III) | 1.51 | 0.76–2.99 | 0.242 |
| Lymphatic vascular invasion | 0.88 | 0.40–1.96 | 0.763 |
| Blood vessel invasion | 1.81 | 0.86–3.78 | 0.114 |
| Perineural invasion | 2.20 | 0.99–4.90 | 0.050 |
| BRAF IHC * (wt/mutant) | 0.25 | 0.05–1.14 | 0.056 |
| MMR status (p/d) | 0.48 | 0.15–1.54 | 0.211 |
| CMS1–CMS2/CMS3 | 1.96 | 0.61–6.34 | |
| CMSCMS1–CMS4 | 4.38 | 0.78–24.5 | 0.224 |
| PD-L1–L | 0.40 | 0.20–0.81 | 0.010 |
| PD-L1–H | 0.41 | 0.15–1.07 | 0.064 |
* Not assessable in four tumor samples. p/dMMR: Mismatch repair proficient or deficient. CMS: Consensus Molecular Subtype. IHC: Immunohistochemical. Statistically significant p values are presented in bold.